You are here

Diyaliz hastalarında inflamasyon nedenleri ve muhtemel tedavi seçenekleri

Share
The causes of the inflammation and possible therapeutic options in dialysis patients
Author Name

Journal Name:

Publication Year:

Volume:

Number:

Sayfa Aralığı:: 
271-276

Publication Language:

Abstract (Original Language): 
Kronik böbrek hastaları ve özellikle diyaliz hastalarında kardiyovasküler morbidite ve mortalite artmıştır. Üremili hastalarda inflamasyon, renal replasman tedavisinden uzun süre önce başlamaktadır. Malnütrisyon ve ateroskleroz gibi önemli parametrelerin yanında inflamasyon, üremik hastalardaki mortalite ve morbiditenin en önemli nedenlerinden birisidir. Kardiyovasküler mortalite ve morbidite ile inflamasyon arasındaki ilişki, hem kronik böbrek hastaları hem de diyaliz hastalarında geçmişte yapılan pek çok çalışma ile gösterilmiştir. Henüz diyalize başlamamış olanlar ve halen diyalize girmekte olan böbrek yetmezliklilerde C-reaktif protein, interlökin-6 ve tümör nekrozis faktör-alfa gibi inflamasyon belirteçlerinde artışlar gösterilmiştir. Bu derlemede diyaliz hastalarındaki inflamasyonun hem muhtemel nedenleri, hem de muhtemel tedavi stratejileri tartışılmaya çalışılmıştır.
Abstract (2. Language): 
Cardiovascular morbidity and mortality are increased in patients with chronic kidney disease and especially dialysis. In patients with uremia, inflammation starts long before renal replacement therapy. Besides the other important parameters such as malnutrition and atherosclerosis, inflammation is one of the most important causes of morbidity and mortality in uremic patients. An association between cardiovascular mortality and morbidity and inflammation in both chronic kidney disease and dialysis patients has been demonstrated by a lot of studies in the past. Inflammation in patients with renal failure who have not yet begun dialysis and in patients receiving dialysis has shown increased levels of inflammatory markers, such as Creactive protein, interleukin-6, tumor necrosis factoralpha. In this review, it is tried to discuss both possible causes of inflammation and possible therapeutic strategies in dialysis patients.

Keywords (Original Language):

REFERENCES

References: 

1. Shlipak MG, Fried LF, Crump C, et al. Elevations of
inflammatory and procoagulant biomarkers in elderly
persons with renal insufficiency. Circulation 2003; 107:
87-92.
2. Oberg BP, McMenamin E, Lucas FL, et al. Increased
prevalence of oxidant stress and inflammation in patients
with moderate to severe chronic kidney disease. Kidney
Int 2004; 65: 1009-1016.
3. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. CReactive protein predicts all-cause and cardiovascular
mortality in hemodialysis patients. Am J Kidney Dis 2000;
35: 469-476.
4. Stenvinkel P, Wanner C, Metzger TG, et al.
Inflammation and outcome in end-stage renal failure:
does female gender constitute a survival advantage?
Kidney Int 2002; 62: 1791-1798.
5. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al.
The prognostic impact of fluctuating levels of C-reactive
protein in Brazilian haemodialysis patients: a prospective
study. Nephrol Dial Transplant 2004; 19: 2803-2809.
6. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular
disease risk factors in chronic renal insufficiency. Clin
Nephrol 2002; 57: 327-335.
7. Muntner P, Hamm LL, Kusek JW, et al. The prevalence
of nontraditional risk factors for coronary heart disease in
patients with chronic kidney disease. Ann Intern Med
2004; 140: 9-17.
8. Culleton BF, Larson MG, Wilson PW, et al.
Cardiovascular disease and mortality in a communitybased cohort with mild renal insufficiency. Kidney Int
1999; 56: 2214-2219.
9. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003 (87): S24-31.
10. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:
1899-1911.
11. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is
a stronger predictor of total and cardiovascular mortality
than C-reactive protein in haemodialysis patients.
Nephrol Dial Transplant 2004; 19: 1154-1160.
12. Honda H, Qureshi AR, Heimburger O, et al. Serum
albumin, C-reactive protein, interleukin 6, and fetuin A as
predictors of malnutrition, cardiovascular disease, and
mortality in patients with ESRD. Am J Kidney Dis 2006;
47: 139-148.
13. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6,
and TNF-alpha: central factors in the altered cytokine
network of uremia--the good, the bad, and the ugly.
Kidney Int 2005; 67: 1216-1233.
14. Wang AY, Sea MM, Tang N, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis
patients. J Am Soc Nephrol 2004; 15: 3134-3143.
15. Miyata T, Sugiyama S, Suzuki D, et al. Increased carbonyl
modification by lipids and carbohydrates in diabetic
nephropathy. Kidney Int Suppl 1999; 71: S54-56.
16. Gutierrez A, Alvestrand A, Wahren J, et al. Effect of in
vivo contact between blood and dialysis membranes on
protein catabolism in humans. Kidney Int 1990; 38: 487-
494.
17. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals
associated with hemodialysis. Kidney Int 2002; 62: 1408-
1416.
18. Schindler R, Boenisch O, Fischer C, et al.. Effect of the
hemodialysis membrane on the inflammatory reaction in
vivo. Clin Nephrol 2000; 53: 452-459.
19. Memoli B, Postiglione L, Cianciaruso B, et al. Role of different dialysis membranes in the release of interleukin-6-
soluble receptor in uremic patients. Kidney Int 2000; 58:
417-424.
20. Carrero JJ, Axelsson J, Avesani CM, et al. Being an
inflamed peritoneal dialysis patient - a Dante's journey.
Contrib Nephrol 2006; 150: 144-151.
21. Vanholder R, Ringoir S. Infectious morbidity and defects
of phagocytic function in end-stage renal disease: a
review. J Am Soc Nephrol 1993; 3: 1541-1554.
22. Kaysen GA. Role of inflammation and its treatment in
ESRD patients. Blood Purif 2002; 20: 70-80.
23. Rahmati MA, Craig RG, Homel P, et al. Serum markers
of periodontal disease status and inflammation in
hemodialysis patients. Am J Kidney Dis 2002; 40: 983-
989.276 · Aralýk 2007 · Gülhane TD Yýlmaz
24. Kshirsagar AV, Moss KL, Elter JR, et al. Periodontal disease is associated with renal insufficiency in the
Atherosclerosis Risk In Communities (ARIC) study. Am
J Kidney Dis 2005; 45: 650-657.
25. van Tellingen A, Grooteman MP, Schoorl M, et al.
Intercurrent clinical events are predictive of plasma Creactive protein levels in hemodialysis patients. Kidney Int
2002; 62: 632-638.
26. Vicente-Martinez M, Martinez-Ramirez L, Munoz R, et
al. Inflammation in patients on peritoneal dialysis is associated with increased extracellular fluid volume. Arch
Med Res 2004; 35: 220-224.
27. Chung SH, Heimburger O, Stenvinkel P, et al.
Association between inflammation and changes in residual renal function and peritoneal transport rate during the
first year of dialysis. Nephrol Dial Transplant 2001; 16:
2240-2245.
28. Ozkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive
drugs. Nephrol Dial Transplant 1998; 13: 1489-1493.
29. Pecoits-Filho R, Stenvinkel P, Wang AY, et al. Chronic
inflammation in peritoneal dialysis: the search for the
holy grail? Perit Dial Int 2004; 24: 327-339.
30. Woodrow G, Turney JH, Brownjohn AM. Technique
failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int 1997; 17: 360-364.
31. Glorieux GL, Dhondt AW, Jacobs P, et al. In vitro study
of the potential role of guanidines in leukocyte functions
related to atherogenesis and infection. Kidney Int 2004;
65: 2184-2192.
32. Vanholder R, Schepers E, Meert N, et al. What is uremia?
Retention versus oxidation. Blood Purif 2006; 24: 33-38.
33. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid
slows loss of residual renal function in new dialysis
patients. Nephrol Dial Transplant 2002; 17: 1814-1818.
34. Schindler R, Beck W, Deppisch R, et al. Short bacterial
DNA fragments: detection in dialysate and induction of
cytokines. J Am Soc Nephrol 2004; 15: 3207-3214.
35. Jaar BG, Hermann JA, Furth SL, et al. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk
factors, and mortality with nondiabetic hemodialysis
patients. Am J Kidney Dis 2000; 35: 282-292.
36. Nassar GM, Ayus JC. Infectious complications of the
hemodialysis access. Kidney Int 2001; 60: 1-13.
37. Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL:
a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc
Nephrol 1998; 9: 869-876.
38. Ayus JC, Sheikh-Hamad D. Silent infection in clotted
hemodialysis access grafts. J Am Soc Nephrol 1998; 9:
1314-1317.
39. Williams B, Layward E, Walls J. Skeletal muscle degradation and nitrogen wasting in rats with chronic metabolic
acidosis. Clin Sci (Lond) 1991; 80: 457-462.
40. Nawrocki A, Scherer PE. The delicate balance between fat
and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharm 2004; 4: 281-
289.
41. Wellen KE, Hotamisligil GS. Inflammation, stress, and
diabetes. J Clin Invest 2005; 115: 1111-1119.
42. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J
Clin Invest 2003; 112: 1796-1808.
43. Yao Q, Axelsson J, Heimburger O, et al. Systemic inflammation in dialysis patients with end-stage renal disease:
causes and consequences. Minerva Urol Nefrol 2004; 56:
237-248.
44. Stenvinkel P, Lindholm B, Heimbürger O. Novel
approaches in an integrated therapy of inflammatoryassociated wasting in end-stage renal disease. Semin Dial
2004; 17: 505-515.
45. Kaizu Y, Ohkawa S, Odamaki M, et al. Association
between inflammatory mediators and muscle mass in
long-term hemodialysis patients. Am J Kidney Dis 2003;
42: 295-302.
46. Johansen Kl, Kaysen GA, Young BS, et al. Longitudinal
study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr
2003; 77: 842-846.
47. Stenvinkel P, Lindholm B, Lönnqvist F, et al. Increases in
serum leptin during peritoneal dialysis are associated with
inflammation and a decrease in lean body mass. J Am Soc
Nephrol 2000; 11: 1303-1309.
48. Ward RA, McLeish KR. Polymorphonuclear leukocyte
oxidative burst is enhanced in patients with chronic renal
insufficiency. J Am Soc Nephrol 1995; 5: 1697-1702.
49. Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed
peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic
oxidative stress in chronic kidney disease. J Am Soc
Nephrol 2005; 16: 2431-2438.
50. Ernst E, Hammerschmidt DE, Bagge U, et al. Leukocytes
and the risk of ischemic diseases. JAMA 1987; 257: 2318-
2324.
51. Weijenberg MP, Feskens EJ, Souverijn JH, et al. Serum
albumin, coronary heart disease risk, and mortality in an
elderly cohort. Epidemiology 1997; 8: 87-92.
52. Reddan DN, Klassen PS, Szczech LA, et al. White blood
cells as a novel mortality predictor in haemodialysis
patients. Nephrol Dial Transplant 2003; 18: 1167-1173.
53. Pifer TB, McCullough KP, Port FK, et al. Mortality risk
in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
54. Allende LM, Corell A, Manzanares J, et al.
Immunodeficiency associated with anorexia nervosa is
secondary and improves after refeeding. Immunology
1998; 94: 543-551.
55. Sjoland JA, Pedersen RS, Jespersen J, et al. Intraperitoneal
heparin ameliorates the systemic inflammatory response
in PD patients. Nephron Clin Pract 2005; 100: c105-110.

Thank you for copying data from http://www.arastirmax.com